The major mechanisms of resistance to these cytosine nucleoschedule of 5-Aza-CdR should be based on the kinetic paraside analogues are summarized in Table 1 . Both 5-Aza-CdR
Introduction
The methylation in DNA of cytosine to 5-methylcytosine in 5-Aza-2Ј-deoxycytidine (5-Aza-CdR; Decitabine) was first the promoter region of a gene can suppress its expression. 15 shown to be an active antileukemic agent in a mouse model As shown in Figure 1 the incorporation of 5-Aza-CdR into by Sorm and Vesely. 1 In the mouse L1210 leukemia model, DNA can block DNA methylation 11, 16 which can result in 5-Aza-CdR was demonstrated to be much more effective than gene activation and the induction of differentiation. [16] [17] [18] cytosine arabinoside (Ara-C), 2 one of the most effective agents Recent investigations have shown that the lack of for the treatment of acute myeloid leukemia. 3 In vitro studies expression of several types of tumor (growth) suppressor genes showed that 5-Aza-CdR is also a more potent antineoplastic is due to aberrant DNA methylation. 19 As summarized in agent against human myeloid leukemic cells than Ara-C. 4 Table 2, 5-Aza-CdR has been demonstrated to activate the Phase I-II studies in Canada and Europe on 5-Aza-CdR expression of tumor suppressor genes: p16, 20,21 p15, 22 VHL 23 showed that this cytosine analogue could induce complete and retinoic acid receptor ␤ (RAR␤) 24 that have been silenced remission in patients with acute leukemia who had relapsed by DNA methylation. Recent reports support the hypothesis on conventional chemotherapy. [5] [6] [7] In addition, 5-Aza-CdR has that RAR␤ is a tumor suppressor gene. 25, 26 shown clinical activity in patients with myelodysplastic synThe role of most tumor suppressor genes in the pathogenesis action is also schedule-dependent. At diagnosis or relapse, the leukemic patient may have 10 9 to 10 10 leukemic stem cells that should be eradicated by treatment in order to produce curative therapy. To accomplish this difficult task, every parameter that can influence the response to the 5-Aza-CdR should be evaluated. In Table 3 are summarized the major parameters that should be taken into account in the design of the optimal dose schedule for 5-Aza-CdR.
Chemotherapy studies in mice with leukemia showed that 5-Aza-CdR treatment produces 'cures' only at the higher dose levels. 31 Extrapolation to the clinical therapy of leukemia, the higher dose ranges of 5-Aza-CdR should be given a priority. The steady state plasma concentration of 5-Aza-CdR during a centrations of 5-Aza-CdR will be obtained in all anatomical compartments. In certain anatomical sites the concentration of 5-Aza-CdR will be less than that of the plasma concen- What is the optimal plasma concentration of 5-Aza-CdR? Clinical studies on Ara-C have shown that it is possible to use very high doses with cytosine nucleoside analogues for the of leukemia is unclear at this time since DNA methylation studies have been performed primarily on tumor cells. The therapy of leukemia. 36 However, very high doses can produce unexpected side-effects such as the neurological toxicity that tumor suppressor gene p16 does not appear to be modified by methylation in leukemia. 22 However, the p15 tumor supsometimes is produced by high dose Ara-C therapy. 37 Since intermediate dose Ara-C therapy can produce similar pressor gene was demonstrated to be hypermethylated in leukemic cells in six of seven patients with AML and four of eight responses as high-dose therapy, 3 it is reasonable to also favor the use of intermediate dose 5-Aza-CdR for the therapy of leupatients with ALL. 22 The p15 gene is a cyclin-dependent kinase inhibitor. 27 Cyclin-dependent kinases play an important kemia. The optimal plasma concentration for 5-Aza-CdR is probably in the range of the K m value of deoxycytidine kinase, role in the regulation of cellular progression into the S phase and the control of cell proliferation.
the rate limiting enzyme that activates this analogue. 32 The K m is the concentration of drug at which the enzyme reaction In order for tumor suppressor genes to participate in cellular transformation, both alleles must be inactivated. Inactivation takes place at 50% of its maximum velocity. For deoxycytidine kinase the K m of 5-Aza-CdR is in the range of approxiof tumor suppressor genes can occur by chromosomal deletion or rearrangement, mutation and DNA methylation. In mately 10
−5 M. 32 In order to obtain a plasma concentration of this range, 5-Aza-CdR should be infused at a rate of about 1-evaluation of the clinical response of leukemic patients to 5-Aza-CdR, the prior chemotherapy should be examined. As 2 mg/kg/h or 30-60 mg/m 2 /h. 5, 6 The pharmacokinetics of 5-Aza-CdR are also important. Since 5-Aza-CdR has a short illustrated in Figure 2 , prior treatment with mutagenic or DNA damaging anticancer drugs have the potential to produce plasma half life of 15-20 min, 6 a constant continuous i.v. infusion of this analogue is the best way to maintain a steady mutations and chromosomal translocations 28 that can inactivate tumor suppressor genes and possibly decrease the state level of approximately 10 −5 M in the plasma. The duration of the 5-Aza-CdR therapy will depend on the response to subsequent therapy with 5-Aza-CdR.
cell cycle parameters of the leukemic cells and the normal hematopoietic stem cells. Recent investigations on the cell kinetics of myeloid leukemic cells in man gave an estimate of Optimization of dose schedule of 5-Aza-CdR the length of the cell cycle with a mean value of 59.8 h (range 18-211 h). 38 From these data the estimated optimal duration The classical investigation by Skipper et al 29 demonstrated that the antileukemic activity of the S phase specific agent, of 5-Aza-CdR therapy is probably in the range of 90 h (only six of 45 patients showed a cell cycle time Ͼ90 h). Ara-C, was markedly schedule-dependent in murine leukemia models. These data plus additional data on the pharmacology
The 5-Aza-CdR therapy will also induce terminal differentiation of the dividing hematopoietic progenitor cells. Thereof Ara-C were used by Momparler 30 to propose a model for the therapy of leukemia with this analogue. Since 5-Aza-CdR fore, the success of the therapy depends on the survival of the resting hematopoietic stem cells. If prior therapy with other is also an S phase specific agent, its in vivo antileukemic Tumor (growth) suppressor gene can be inactivated by either mutation (M), chromosomal deletion or DNA methylation (CH 3 ). Both alleles of the tumor suppressor gene must be inactivated to result in a complete loss of expression. Prior treatment with mutagenic or DNA damaging drugs by inactivation of both alleles can reduce the clinical response to 5-Aza-CdR.
Table 3
Parameters to consider in the design of optimal dosegation in our laboratory is to use gene therapy to protect the schedule of 5-Aza-CdR for the therapy of leukemia normal hematopoietic stem cells from drug-induced toxicity.
The enzyme cytidine deaminase, as discussed above, inacti- Ara-C by deamination. We have cloned the human cytidine demonstrated that they are drug resistant to Ara-C. 42 We are cells.
currently investigating if these hematopoietic cells are also cross-resistant to 5-Aza-CdR. One problem to overcome before this type of gene therapy can be used clinically is the accidental insertion of the cytiddrugs or disease progression produces a marked reduction in ine deaminase gene into a few leukemic cells that may conthe number of these resting stem cells, the 5-Aza-CdR will taminate a normal marrow aspirate. Future technological produce a prolonged granulocytopenia. Under these conadvances in the cloning of normal hematopoietic stem cells ditions a more conservative approach to therapy with 5-Azacan overcome this problem. In addition, if the leukemic cells CdR should be used.
have an identifiable genetic marker that can be detected by the polymerase chain reaction, the possible contamination by leukemic cells can be verified prior to transplantation of the Approaches to overcome the problem of hematopoietic normal stem cells. toxicity
Hematopoietic growth factors, such as G-CSF or GM-CSF, are
In vitro assays to evaluate clinical response currently used to reduce the duration of leukopenia following therapy with cytotoxic anticancer agents. 39 We have observed Since a conventional clinical trial on an experimental therapy for leukemia can take up to 5 years and a significant number a gradual reduction in the white blood cell count (WBC) following therapy with 5-Aza-CdR, 5, 6 which one would expect of patients for complete evaluation, in practice only a very small number of trials can be performed. This poses a serious for an agent that induces cellular differentiation. The terminal differentiation of the dividing hematopoietic progenitor cells problem for an agent such as 5-Aza-CdR whose clinical efficacy is dose-schedule dependent. One approach to overcome induced by 5-Aza-CdR is a slow process requiring many days and thus the feedback mechanism to activate the recruitment this problem is to perform a small series of pilot studies in which in vitro tests before and after therapy are used to evaluof resting hematopoietic stem cells into the proliferation compartment may take place much later in time than produced ate efficacy in conjunction with the conventional clinical response end points. For example, we have used an in vitro by cytolytic drugs. If these conditions exist, treatment with G-CSF or GM-CSF after 5-Aza-CdR therapy may reduce the drug sensitivity test to evaluate the response of leukemic patients to 5-Aza-CdR. We observed in some patients that the duration of granulocytopenia.
Another approach to overcome the problem of hematopoleukemic cells that survived the 5-Aza-CdR treatment showed drug resistance. 5, 6, 13 One possible interpretation of these data ietic toxicity produced by 5-Aza-CdR which is under investi-is that the dose schedule of 5-Aza-CdR used was capable of kemic blasts without any sign of drug toxicity (Momparler RL, Rivard GE, unpublished observation). In accordance with this eradicating all of the drug-sensitive leukemic blasts, but not the small fraction of drug-resistant leukemic cells. One observation is our mouse study, using L1210 leukemic cells that are drug resistant due to the deficiency in deoxycytidine important conclusion in this type of analysis is that only an 'optimal' dose schedule of 5-Aza-CdR can eliminate all the kinase, in which we demonstrated that 3-DU markedly increased the effectiveness of therapy with 5-Aza-CdR. 10 drug-sensitive leukemic blasts and permit the survival of the drug-resistant cells. Using this approach it should be possible to evaluate different dose schedules of 5-Aza-CdR in a period of months instead of years by the conventional method and it Differentiation therapy of leukemia will also require fewer patients.
The spontaneous frequency of mutation in mammalian cells One important aspect of the action of 5-Aza-CdR is its capacity to induce leukemic cell differentiation. 17,18 Since a for a single copy gene is about 10
. 9 Since a cell contains two copies of the autosomal gene, deoxycytidine kinase, the very large number of leukemic cells must be eradicated by the 5-Aza-CdR therapy, the possibility exists that a very small theoretical predicted frequency of drug resistance due to a complete loss of enzyme activity due to a mutation in each fraction of the leukemic cell population will not reach the threshold level of gene expression so as to undergo irreversallele of this gene is 10 −10 (10
). This means that theoretically one cell in about 10 billion leukemic stem cells would ible terminal differentiation. This subpopulation of leukemic cells may survive the 5-Aza-CdR treatment. One approach to be drug resistant due to the complete loss of deoxycytidine kinase activity. Therefore, the 5-Aza-CdR therapy would have overcome this problem is to use other differentiation agents in combination with 5-Aza-CdR. The remarkable observation to produce about a 10-log reduction in leukemic stem cells in order to permit survival of a leukemic cell with this type of that retinoic acid can induce complete remission of patients with acute promyelocytic leukemia 48, 49 suggests that this vitdrug resistance. Only the 'optimal' dose schedule of 5-AzaCdR can produce a reduction in the number of leukemic stem amin A metabolite may be a good agent to test in combination with 5-Aza-CdR. In vitro studies have shown an additive anticells of such a magnitude. If prior to 5-Aza-CdR treatment, the leukemic patient is treated with a mutagenic drug, one would neoplastic effect of retinoic acid in combination with 5-AzaCdR on human myeloid leukemic cells. 50 Vitamin D 3 which predict an increase in the frequency of drug resistance.
As discussed earlier, lack of response to 5-Aza-CdR therapy can also induce differentiation of leukemic cells was demonstrated to produce a synergistic antineoplastic effect in combican also be due to deletions, mutations or DNA hypermethylation in tumor suppressor genes. In vitro tests, such as by nation with 5-Aza-CdR on human myeloid leukemic cells.
51
Vitamin D analogues which have reduced calcium toxicity Southern blotting with specific DNA probes to the region of the first exon after digestion of genomic DNA with methylmay be interesting agents to use in combination with 5-AzaCdR in phase I studies in leukemia. 52 Interferon-␣ also has ation-sensitive and insensitive restriction enzymes can be used to detect tumor suppressor genes that have been silenced by some potential to induce leukemic cell differentiation and has shown an interesting interaction with 5-Aza-CdR on human DNA hypermethylation. [20] [21] [22] [23] In addition, novel techniques have been developed to identify the specific sites of cytosine myeloid leukemic cells. 53 An interesting differentiating agent to investigate for use in combination with 5-Aza-CdR is methylation by DNA sequencing. [43] [44] [45] These in vitro tests which can be performed on the leukemic cells before and hexamethylene bisacetamide which has been evaluated in patients with myeloid leukemia and myeodysplastic after treatment with 5-Aza-CdR will assist in the evaluation of the clinical response to 5-Aza-CdR.
syndrome.
54
The action of steroids on leukemic cells is also an interesting area of investigation. It should be pointed out that 5-AzaCdR treatment of a steroid-resistant T lymphoid leukemic cell Approaches to overcome the problem of drug resistance line produced an increased sensitivity to the cytolytic effects of dexamethasone, 55 suggesting that this cytosine analogue The use of other antileukemic agents in combination with the 5-Aza-CdR therapy is the conventional way to overcome the may be an effective therapeutic agent for the treatment of steroid-resistant lymphoid leukemias. Remarkably, estrogen problem of drug resistance to this cytosine analogue. The choice of drug and its time of administration should be carereceptor expression is silenced by DNA methylation in most hematological neoplasms suggesting that modification of its fully chosen. As discussed above, the use of a mutagenic or DNA damaging antileukemic drug prior to or simultaneously gene may be one of the early events in the pathogenesis of leukemia and suggesting a possible therapeutic role of dewith the 5-Aza-CdR therapy is not recommended.
Interesting experimental agents that can be used in combimethylating agents. 56 In this regard, it is interesting to note that 5-Aza-CdR was demonstrated to activate estrogen recepnation with 5-Aza-CdR are 3-deazauridine (3-DU) and cyclopentyl-cytosine (CPC). 3-DU and CPC are biochemical modutor (ER) expression in ER-negative breast cancer cells by demethylation of its gene.
57
lators which inhibit CTP synthetase resulting in a secondary reduction in the intracellular pool of dCTP. 46, 47 As discussed above, one mechanism of resistance to 5-Aza-CdR is an increased pool of dCPT. Using in vitro studies with leukemic Conclusions cells we demonstrated a synergistic antineoplastic action when either 3-DU or CPC were used in combination with 5- The novel mechanism of action of 5-Aza-CdR in the activation of tumor (growth) suppressor and differentiation genes and its Aza-CdR. One very interesting aspect about 3-DU is that cells that are lacking deoxycytidine kinase activity are very sensipotent antileukemic activity in animal models make it a very interesting agent to investigate in the therapy of leukemia. tive to the cytotoxic action of this analogue. In one terminal leukemic patient that was treated with 5-Aza-CdR, we
Since it is an S-phase specific agent and its antileukemic activity is dose-schedule dependent, a careful analysis of its detected drug resistance due to a deficiency in deoxycytidine kinase; 3-DU therapy completely eliminated the blood leupharmacology is essential in order to design its optimal dose 
